Three Cases of Methotrexate-associated Lymphoproliferative Disorder (MTX-LPD)
| Autor: | Naoki Kanai, Yoshiya Ishida, Yuuki Kobayashi, Yasuaki Harabuchi, Tetsuji Wada, Atsuyoshi Asahi, Shigetaka Moriai, Kan Kishibe |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty medicine.medical_treatment Lymphoproliferative disorders Gastroenterology Arthritis Rheumatoid immune system diseases hemic and lymphatic diseases Internal medicine Biopsy medicine Humans heterocyclic compounds skin and connective tissue diseases Aged Chemotherapy medicine.diagnostic_test business.industry medicine.disease Lymphoproliferative Disorders Lymphoma Methotrexate medicine.anatomical_structure Otorhinolaryngology Rheumatoid arthritis Tonsil Total dose Female business medicine.drug |
| Zdroj: | Nippon Jibiinkoka Gakkai Kaiho. 111:594-598 |
| ISSN: | 1883-0854 0030-6622 |
| Popis: | Methotrexate (MTX) has been increasingly administered to patients with rheumatoid arthritis (RA), resulting in methotrexate-associated lymphoproliferative disorder (MTX-LPD) in patients. We reported three case of rheumatoid arthritis (RA) undergoing methotrexate (MTX) therapy who developed MTX-LPD. A 72-year-old woman treated with MTX since December 1997 (total dose 3684 mg) presented with swelling of the right tonsil in October 2006, and diffuse large B-cell lymphoma was diagnosed by tonsil biopsy and positive EBER1. When MTX therapy was interrupted, the tonsil was shrank and chemotherapy was not necessary. She followed a good clinical course for 12 months. Two other patients treated with MTX for RA for several years presented with enlarged neck lymph nodes and were diagnosed with MTX-LPD. Neck lymph nodes shrank upon MTX withdrawal in several weeks. There have been no signs of recurrence in these cases and they followed a good clinical course. The oncogenic potential of MTX and RA is reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|